Share on StockTwits

Analysts at HC Wainwright lifted their price target on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from $21.00 to $24.00 in a research report issued to clients and investors on Friday. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 134.83% from the company’s current price.

BioCryst Pharmaceuticals (NASDAQ:BCRX) opened at 10.22 on Friday. BioCryst Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $13.33. The stock’s 50-day moving average is $8.61 and its 200-day moving average is $8.9. The company’s market cap is $613.9 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.17). The company had revenue of $3.50 million for the quarter, compared to the consensus estimate of $3.34 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was down 2.8% on a year-over-year basis. Analysts expect that BioCryst Pharmaceuticals will post $-0.75 EPS for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Roth Capital raised their price target on shares of BioCryst Pharmaceuticals from $18.00 to $20.00 in a research note on Wednesday. Separately, analysts at Bank of America reiterated a “positive” rating on shares of BioCryst Pharmaceuticals in a research note on Wednesday. Finally, analysts at Brinson Patrick initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, April 14th. They set an “outperform” rating and a $15.00 price target on the stock. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $18.29.

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) is a biotechnology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.